Covid-19: What is the evidence for the antiviral molnupiravir?
Andy Extance
Abstract
Merck’s drug was originally claimed to halve hospital admissions and deaths in people with covid-19, leading some governments to stockpile it as the pandemic continued. <b>Andy Extance</b> looks at the published evidence for its effectiveness
Topics & Concepts
StockpileCoronavirus disease 2019 (COVID-19)PandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyMedicineAntiviral drugPolitical scienceOutbreakVirusLawInternal medicineDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchInfectious Encephalopathies and Encephalitis